However, preclinical studies with a bispecific FCRL5/CD3 mAb has shown encouraging activity against patient myeloma cells, can deplete B cells and bone marrow plasma cells in cynomolgus monkeys, and exhibits enhanced activity when combined with PD-L1 blockade (40). The gene discussed is FCRL5; the disease is plasma cell myeloma.